Key takeaways:
Direct-acting antiviral (DAA) therapy can cure hepatitis C.
DAA therapy is more effective than older medicines and has fewer side effects.
DAA therapy is very expensive, but it is usually covered by insurance. And you may be able to enroll in a patient assistance program to make them more affordable.
Hepatitis C is a curable disease. After decades of being dubbed “the silent killer,” the hepatitis C virus can now be detected easily in a clinic or pharmacy near you. And in many cases, it can be cured with new medications called direct-acting antivirals (DAAs).
Hepatitis C, or hep C, is an infection of the liver caused by the hepatitis C virus. It passes from person to person through contact with blood that has the virus. Most people who come in contact with the virus develop chronic hepatitis C. Chronic hepatitis C can slowly destroy the liver and cause liver failure if it’s not treated. It can also cause a type of liver cancer called hepatocellular carcinoma.
Yes, hepatitis C is now curable.
New medications called DAAs can cure hepatitis C in most patients. This means people can avoid complications, like liver failure and liver cancer.
But, there is a catch: These drugs are expensive and accessing them can be complicated.
In the past, treatment for hepatitis C included interferon, a medication with many unpleasant side effects and risks. Also, the cure rates were not that great either. But new treatments for hep C are all “interferon-free.” This means that they have fewer side effects.
The new medications to treat hepatitis C are known as direct-acting antiviral (DAA) therapies. These medications work by blocking proteins that normally help the hepatitis C virus to replicate. Some of the most commonly used DAAs for treating hepatitis C are:
Along with having fewer side effects than interferon-based treatments, DAAs also:
Have shorter treatment lengths (8 to 12 weeks)
Can be taken by mouth
Are taken once a day
Have high cure rates (95% to 100%)
DAAs are expensive. Their average cash prices typically start at more than $10,000 for a month’s supply. Many people may pay less using their insurance and/or various assistance programs.
But, hepatitis C treatment is covered by most insurance plans. So for many people, the most cost-effective way of getting it will be through insurance. But even then, you may face restrictions — such as prior authorization or step therapy — before you can get your preferred medication.
If DAAs are not covered by your insurance, ask your healthcare provider about an appeal. The exact process will depend on your insurance provider.
You can also save money with manufacturer copay cards and patient assistance programs. Manufacturer copay cards help you afford your expensive medications by lowering your out-of-pocket costs. When you use a copay card, the manufacturer will pay some or all of the medication costs not covered by your insurance (commercial or private). If you have government health insurance, such as Medicaid or Medicare, you are not eligible for the program.
That said, some examples of copay savings programs for hep C treatment include:
If you have low income or are uninsured, patient assistance programs can help you get your medication for little to no cost. But, you will need your prescriber’s help to fill out the forms and apply. Gilead Support Path and AbbVie both offer patient assistance programs to help people afford the cost of hep C medications, like Mavyret, Harvoni, and Epclusa.
Always make sure to talk with your healthcare provider about your options. You may be able to save money by taking generic instead of brand-name medication, or by filling a 90-day supply instead of a 30-day supply.
There are some other — equally effective — hep C treatments. But you may need to do additional blood testing upfront and take more than 1 tablet per day. These hep C medications include:
Another hepatitis C medication that is sometimes added to DAA treatment is Virazole (Ribavarin).
All the DAAs work really well. There is a high cure rate no matter which medication you take. The best hepatitis C treatment for you depends on:
Whether or not you have been treated for hepatitis C in the past
The specific type of hepatitis C you have (called the genotype)
Your health history
Cost and availability of the medication
A healthcare provider can make sure your hepatitis C is cured using a blood test. About 12 weeks after you finish treatment, you’ll have a blood test to measure how much hepatitis C virus is in your blood. If there’s no virus in your blood, this is called a “sustained virologic response” or SVR for short. If you have an SVR, you are most likely cured. Studies show us that 98% to 99% of patients with an SVR at 12 weeks are permanently cured of hepatitis C.
So, to be clear: New hepatitis C treatments cure hepatitis C more than 95% of the time. And a simple blood test 12 weeks after you finish treatment will confirm that this is the case.
If you’ve had treatment for hep C before and it didn’t work, don’t despair. The new treatments we talked about here still have great cure rates (more than 95%) — even if older treatments didn’t work for you. The choice of treatment will depend on what you’ve already tried, what other medications you currently take (if any), and — as always — cost and availability.
Older treatments for hepatitis C had many side effects and were not that effective. But newer direct-acting antivirals (DAAs) can cure hepatitis C for most people. There are several different DAAs that treat hepatitis C, and they all work equally well. Still, the best option for you depends on your medical history and the specific type of hepatitis C virus in your blood. Hepatitis C treatment can be expensive with a month supply starting at almost $10,000. But insurance coverage and manufacturer discount programs can make DAA therapies more affordable.
American Association for the Study of Liver Diseases and Infectious Disease Society of America. (2021). Simplified HCV treatment for treatment-naive adults without cirrhosis.
Centers for Disease Control and Prevention. (n.d.). Get tested: National HIV, STD, and hepatitis testing.
Centers for Disease Control and Prevention. (2020). Hepatitis C questions and answers for the public.
El Kassas, M., et al. (2020). Retreatment of chronic hepatitis C patients who failed previous therapy with directly acting antivirals: A multicenter study. International Journal of Infectious Diseases.
Epclusa. (n.d.). Check your co-pay coupon eligibility.
Geddawy, A., et al. (2017). Direct acting anti-hepatitis C virus drugs: Clinical pharmacology and future direction. Journal of Translational Internal Medicine.
Ghany, M. G., et al. (2019). Hepatitis C guidance 2019 update: American Association for the Study of Liver Diseases-Infectious Disease Society of America recommendations for testing, managing, and treating hepatitis C virus infection. Hepatology.
Gilead. (n.d.). Welcome to support path.
Harvoni. (n.d.). Eligible patients may pay as little as $5 per co-pay for Harvoni.
Mavyret. (n.d.). Cost.
McHutchinson, J. G., et al. (2009). Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. The New England Journal of Medicine.
Sandmann, L., et al. (2019). Treatment of chronic hepatitis C: Efficacy, side effects and complications. Visceral Medicine.
Smith-Palmer, J., et al. (2015). Achieving sustained virologic response in hepatitis C: A systematic review of the clinical, economic and quality of life benefits. BMC Infectious Diseases.
U.S. Department of Health and Human Services. (2020). Hepatitis C basic information.
U.S. Department of Veterans Affairs. (2019). Viral hepatitis and liver disease.